印度制药行业-英-70页_1mb

Executive Summary

The Indian pharmaceutical industry is poised for significant growth, with exports projected to reach $27 billion in FY2023 and the market expected to value $130 billion by 2030. Key drivers include low production costs, a large domestic market, and regulatory frameworks like the Drugs and Cosmetics Act. The industry faces challenges from global pandemics, pricing controls, and complex entry strategies, but is supported by government incentives and innovations in clinical trials and manufacturing.

Introduction

India's pharmaceutical sector has seen substantial growth, driven by foreign direct investment (FDI) and mergers & acquisitions. Opportunities include low-cost R&D, USFDA approvals, and clinical trial hubs. However, entry strategies must navigate complexities in entity formation, with the sector evolving post-TRIPS to balance intellectual property and public health needs.

India Entry Strategies

Entering the Indian market requires considering investment climate factors, production-linked incentives (PLI schemes), and entity structures like branches or subsidiaries. Legal and tax considerations under the Companies Act and indirect taxes like GST are crucial, with India's Patent Act offering post-TRIPS compliance protections.

Legal and Regulatory Regime

The industry is heavily regulated by laws such as the Drugs and Cosmetics Act (DCA) 1940, Good Manufacturing Practices (GMP), and pricing controls via the Drug Price Control Order (DPCO). Clinical trials, imports, and manufacturing each have specific requirements, with recent Proposed Drug Law aiming to streamline online pharmacy regulations.

Tax Regime

Direct taxes include corporate tax rates (25% for domestic companies) and incentives for R&D, while indirect taxes involve GST and customs duties. Key challenges include transfer pricing issues and ensuring compliance with tax treaties to avoid double taxation in international dealings.

Key Issues and Challenges

The industry grapples with price controls from DPCO, labeling inconsistencies, GMP non-compliances leading to import bans, and fixed-dose combination approvals. Environmental regulations and anti-corruption frameworks under the Prevention of Corruption Act add compliance burdens.

Conclusion

The Indian pharmaceutical industry offers immense potential for growth and outsourcing, supported by regulatory developments. Success hinges on navigating complex legal, regulatory, and tax landscapes, particularly in clinical trials, intellectual property, and pricing frameworks.